The facility – a 24,000 sq ft plant – will provide contract manufacturing of primary and secondary packaging for trials, working with both early and late phase products. It will also provide labelling, distribution and warehouse services.
The firm says it will continue to work with its US customers, but will also look to work with European clinical trials through the expansion.
CEO and president Derek Hennecke said the move will allow the firm to continue its growth plans after “whethering an economic crisis”.
The new facility is the firm’s second in a year following additions to its headquarters in 2011 .
Hennecke said the move allows the company to access what he believes is a talent pool in the area.
“We love being in Tampa, because through USF, UF and Tampa's growing biotech community, we have access to scientists at the height of their field,” he said.
“We don't have to go far to find people who thrive on the challenge of working with different molecules, upholding rigorous Food and Drug Administration (FDA) standards while also demonstrating the agility to meet client parameters for speed, cost and efficiency.”
And according to the Tampa Hillsborough Economic Development Corporation – a local business recruitment economic development team – we should soon expect to see more pharma growth in the area.
Rick Homans, president and CEO of the corporation said: “Their [Xcelience] continued growth and expansion is a testament to the quality of our workforce, and their presence is a significant asset as we work to expand our life sciences industry.”